Published Online
on December 2, 2002

A more recent version of this article appeared on January 7, 2003

This Article Full Text (PDF) All Versions of this Article: 107/1/17    most recent 01.CIR.0000047062.03282.A3v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Undas, A. Articles by Szczeklik, A. Search for Related Content PubMed PubMed Citation Articles by Undas, A. Articles by Szczeklik, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Related Collections Coagulation Fibrinogen/fibrin Thrombin Platelet function inhibitors Thrombosis risk factors Genetics of cardiovascular disease

Submitted on August 9, 2002
Revised on October 22, 2002
Accepted on October 30, 2002

Aspirin Alters the Cardioprotective Effects of the Factor XIII Val34Leu Polymorphism

Anetta Undas MD, PhD, Wojciech J. Sydor MD, Kathleen Brummel PhD, Jacek Musial MD, PhD, Kenneth G. Mann PhD^*, and Andrew Szczeklik MD, PhD

From the Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland (A.U., W.J.S., J.M., A.S.); and the Department of Biochemistry, University of Vermont, Burlington (K.B., K.G.M.).

^* To whom correspondence should be addressed. E-mail: kmann{at}zoo.uvm.edu.

Background—The mechanism underlying decreased risk for myocardial infarction in carriers of the Leu34 polymorphism of the factor (F) XIII A-subunit is unclear. Given that acetylation of fibrinogen by aspirin can alter its clotting properties and the presence of fibrin stimulates thrombin-mediated activation of FXIII, we have tested the hypothesis that treatment with aspirin differentially modulates the influence of the FXIII Val34Leu polymorphism on its activation in vivo.

Methods and Results—The rates of the disappearance of FXIIIA chain and the appearance of its activated form (FXIIIAa) in sequential 30-second blood samples collected at the site of microvascular injury were compared in 14 healthy carriers of the Leu34 allele and 23 Val34 homozygotes both before and after a 7-day aspirin ingestion (75 mg/d), with the use of quantitative Western blotting. The presence of the Leu34 allele was associated with a significant increase in the maximum rate of FXIII activation by thrombin. Although the Leu34-positive and -negative subjects were similar with respect to aspirin-related impairment of thrombin generation, aspirin led to a more pronounced inhibition of the activation of FXIII in the Leu34 carriers as compared with the Val34 homozygotes.

Conclusions—Inhibition of FXIII activation by aspirin is enhanced in the Leu34 carriers in vivo, suggesting that these subjects might benefit more than the Leu34-negative subjects from the reduction in risk for myocardial infarction with low-dose aspirin.

Key words: genetics • aspirin • coagulation

This article has been cited by other articles:

				F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1041 - 1057. [Abstract] [Full Text] [PDF]

				R.A. Ajjan, K.F. Standeven, M. Khanbhai, F. Phoenix, K.C. Gersh, J.W. Weisel, M.T. Kearney, R.A.S. Ariens, and P.J. Grant Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 712 - 717. [Abstract] [Full Text] [PDF]

				Y. Nakano, H. F. Al-Jallad, A. Mousa, and M. T. Kaartinen Expression and Localization of Plasma Transglutaminase Factor XIIIA in Bone J. Histochem. Cytochem., July 1, 2007; 55(7): 675 - 685. [Abstract] [Full Text] [PDF]

				J. Nishioka and S. Goodin Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 85 - 97. [Abstract] [PDF]

				D. J. Schneider On Defining Aspirin Resistance J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1710 - 1711. [Full Text] [PDF]

				R. Gonzalez-Conejero, J. Rivera, J. Corral, C. Acuna, J. A. Guerrero, and V. Vicente Biological Assessment of Aspirin Efficacy on Healthy Individuals: Heterogeneous Response or Aspirin Failure? Stroke, February 1, 2005; 36(2): 276 - 280. [Abstract] [Full Text] [PDF]

				A. K. Wittkowsky Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 308 - 316. [Abstract] [PDF]

				H. Tammen, T. Mohring, M. Kellmann, A. Pich, H. H. Kreipe, and R. Hess Mass Spectrometric Phenotyping of Val34Leu Polymorphism of Blood Coagulation Factor XIII by Differential Peptide Display Clin. Chem., March 1, 2004; 50(3): 545 - 551. [Abstract] [Full Text] [PDF]